<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534582</url>
  </required_header>
  <id_info>
    <org_study_id>HLX14-001</org_study_id>
    <nct_id>NCT04534582</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Parallel, Single-Dose, Subcutaneous Injection, Phase I Clinical Study Of HLX14 Versus Prolia® (Denosumab) In Chinese Healthy Adult Male Subjects For Comparison In Pharmacokinetic Characteristics, Safety, And Immunogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, single-dose, subcutaneous injection, parallel study designed to compare&#xD;
      the PK of HLX14 and EU-sourced Prolia® in healthy Chinese adult male subjects, and to assess&#xD;
      the safety, tolerability, and immunogenicity of these 2 drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Area under the serum concentration-time curve from time 0 to the last concentration-quantifiable time t of denosumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Maximum serum concentration following administration of denosumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Area under the serum concentration-time curve from time 0 to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Time to reach maximum serum concentration following administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Total clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Apparent terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Elimination half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC0-t</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Area under the effect-time curve from time zero to last time of quantifiable concentration of Serum CTX1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imin</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Minimum observed plasma concentration of Serum CTX1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imax</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Maximum Percent Inhibition of Serum CTX1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmin</measure>
    <time_frame>from 0 to day 183</time_frame>
    <description>Time to reach Imin of Serum CTX1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>HLX14 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX14 are given subcutaneous injection at a single dose of 60 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-Prolia® group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX14</intervention_name>
    <description>healthy volunteers receive HLX14 (60mg) once</description>
    <arm_group_label>HLX14 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU-Prolia®</intervention_name>
    <description>healthy volunteers receive EU-Prolia® (60mg) once</description>
    <arm_group_label>EU-Prolia® group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males aged ≥ 18 and ≤ 65 years;&#xD;
&#xD;
          2. Body weight ≥ 50 kg, body mass index (BMI) = body weight (kg)/body height2 (m2), BMI ≥&#xD;
             19 and ≤ 26 kg/m2;&#xD;
&#xD;
          3. With no disease history, or with abnormal prior medical history which has no effect on&#xD;
             the trial as judged by the physician;&#xD;
&#xD;
          4. Normal or abnormal without clinical significance in physical examination, vital signs,&#xD;
             ECG, chest imaging, clinical laboratory test, etc.;&#xD;
&#xD;
          5. Before the trial, sign the informed consent form (ICF) and have a full understanding&#xD;
             of trial content, process, and possible adverse events (AEs); be able to complete the&#xD;
             study as per protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With a history of allergy to study drugs, calcium, and/or vitamin D, or with a history&#xD;
             of allergy to drugs or others not suitable for participating in this study as judged&#xD;
             by the investigators;&#xD;
&#xD;
          2. With the following clinically significant diseases (including but not limited to&#xD;
             digestive system, kidney diseases, liver diseases, nervous diseases, blood system,&#xD;
             endocrine system, tumor, respiratory system, immune diseases, mental diseases, or&#xD;
             cardiovascular and cerebrovascular diseases);&#xD;
&#xD;
          3. With a history of upper respiratory tract infection and other acute infections within&#xD;
             2 weeks prior to screening;&#xD;
&#xD;
          4. Occurred or suffering from osteomyelitis or ONJ (Osteonecrosis of the jaw) previously.&#xD;
             The dental or jaw disease that is active, requiring oral surgery; or dental or oral&#xD;
             surgery wounds have not healed; or planned for invasive dental surgery during the&#xD;
             study.&#xD;
&#xD;
          5. With rash, scar, tattoo, etc. at administration site that may affect drug absorption;&#xD;
&#xD;
          6. Blood donation or massive blood loss (&gt; 450 mL) within 3 months prior to screening;&#xD;
&#xD;
          7. Use of any prescription drugs, over-the-counter drugs, vitamin products, or&#xD;
             traditional Chinese medicines within 28 days prior to screening;&#xD;
&#xD;
          8. Participation in any drug clinical trials and use of any investigational/comparator&#xD;
             drugs within 3 months prior to screening;&#xD;
&#xD;
          9. Administration of drugs affecting bone metabolism within 6 months before participating&#xD;
             in this study, including but not limited to: bisphosphonates, fluoride, calcitonin,&#xD;
             strontium, parathyroid hormone or its derivatives, vitamin D supplements (&gt; 1000&#xD;
             IU/day), glucocorticoids, anabolic steroids, calcitriol, and diuretics;&#xD;
&#xD;
         10. Use of any biological products or monoclonal antibodies within 6 months prior to&#xD;
             screening;&#xD;
&#xD;
         11. With a history of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of&#xD;
             beer, 25 mL of spirit, or 100 mL of wine), or positive for alcohol breath test;&#xD;
&#xD;
         12. With a history of substance abuse or drug abuse, or positive for drug screen;&#xD;
&#xD;
         13. Positive for tobacco screen;&#xD;
&#xD;
         14. With significant changes in physical activity within 6 months prior to screening, or&#xD;
             not agree to abstain from strenuous physical exercise during the trial;&#xD;
&#xD;
         15. Positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody,&#xD;
             human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody;&#xD;
&#xD;
         16. Abnormal serum calcium level (beyond the laboratory reference range) during the&#xD;
             screening;&#xD;
&#xD;
         17. Body temperature &gt; 37.5 °C; and/or sitting systolic blood pressure (SBP) &gt; 140 mmHg or&#xD;
             &lt; 90 mmHg, and/or diastolic blood pressure (DBP) &gt; 90 mmHg or &lt; 50 mmHg; and/or pulse&#xD;
             rate &gt; 100 beats/min or &lt; 50 beats/min during the screening.&#xD;
&#xD;
         18. Clinically significant abnormal ECG or QTcF &gt; 450 ms during screening, or with a prior&#xD;
             history of clinically significant abnormal ECG;&#xD;
&#xD;
         19. Unwilling to take adequate contraceptive measures from screening to 6 months after the&#xD;
             administration of study drugs. See Appendix 2 for specific contraceptive measures;&#xD;
&#xD;
         20. Subjects who, in the opinion of the investigators, are not eligible to participate in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chaoming Ma, bachelor</last_name>
    <phone>021-33395790</phone>
    <email>Chaoming_Ma@henlius.com</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

